

IMMUNOTHERAPY for Advanced Bladder Cancer:

A STEP FORWARD IN PATIENT CARE

Saturday, 9 December 2017 | 13.00 – 14.00 | Room A, Palexpo | Geneva, Switzerland

~ 1			٠	
1 .	•	-	ш	BO.
V . I	-1	a	ш	•
\sim 1		ч		

Thomas Powles, MBBS, MRCP, MD Barts Cancer Institute Queen Mary University of London London, United Kingdom

Faculty

Aristotle Bamias, MD, PhD National and Kapodistrian University of Athens Athens, Greece

Yohann Loriot, MD, PhD Gustave Roussy Villejuif, France


Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.



prIME Oncology designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Agenda



13.02 How much do you know about immunotherapy for bladder cancer? Thomas Powles, MBBS, MRCP, MD

13.10 The biological basis for checkpoint inhibition in cancer treatment

Aristotle Bamias, MD, PhD

13.22 Q&A

13.25 A giant leap in the treatment options for advanced bladder cancer Yohann Loriot, MD, PhD

13.40 Q&A

13.45 Interactive case-based panel discussion

13.58 Conclusions and prIME Points™ POINTS™ Thomas Powles, MBBS, MRCP, MD

14.00 Adjourn